FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4303473147> ?p ?o ?g. }

• W4303473147 endingPage "e742" @default.
• W4303473147 startingPage "e741" @default.
• W4303473147 abstract "As the world copes with the ongoing COVID-19 pandemic, WHO declared the outbreak of monkeypox virus a global public health emergency on July 23, 2022.1WHOWHO Director-General declares the ongoing monkeypox outbreak a Public Health Emergency of International Concern.https://www.who.int/europe/news/item/23-07-2022-who-director-general-declares-the-ongoing-monkeypox-outbreak-a-public-health-event-of-international-concernDate: July 23, 2022Date accessed: September 28, 2022Google Scholar This zoonotic orthopox DNA virus, related to the virus that causes smallpox, has been described in humans since 1970.2Ladnyj ID Ziegler P Kima E A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo.Bull World Health Organ. 1972; 46: 593-597PubMed Google Scholar In the past 50 years, cases were described in sporadic outbreaks in Africa, typically originating from contact with wildlife reservoirs (particularly rodents).3Centers for Disease Control and PreventionHuman monkeypox—Kasai Oriental, Democratic Republic of Congo, February, 1996–October, 1997.MMWR Morb Mortal Wkly Rep. 1997; 46: 1168-1171PubMed Google Scholar However, in 2022, the near-simultaneous global outbreaks are affecting sexually active gay, bisexual, and other men who have sex with men almost exclusively.4Thornhill JP Barkati S Walmsley S et al.Monkeypox virus infection in humans across 16 countries—April–June, 2022.N Engl J Med. 2022; 387: 679-691Crossref PubMed Scopus (225) Google Scholar Contrary to the COVID-19 pandemic, a vaccine that could be used for monkeypox was already available, but the key challenge has been deploying the vaccine according to global demand that substantially exceeds supply. Given the scarcity, good public health dictates that the vaccines are offered to those at the highest risk—ie, in the current outbreak, sexually active gay, bisexual, and other men who have sex with men who have multiple partners, and who participate in group sex or attend sex on premises venues.5Ministero della SaluteIndicazioni ad interim sulla strategia vaccinale contro il vaiolo della scimmia.https://www.quotidianosanita.it/allegati/allegato1659727637.pdfDate accessed: September 29, 2022Google Scholar It is clear that monkeypox shares the same risk behaviours with other sexually transmitted diseases, most notably HIV. In fact, 41% of monkeypox infections in a large global case series were in people with HIV, and almost 60% of those without HIV were on pre-exposure prophylaxis (PrEP).4Thornhill JP Barkati S Walmsley S et al.Monkeypox virus infection in humans across 16 countries—April–June, 2022.N Engl J Med. 2022; 387: 679-691Crossref PubMed Scopus (225) Google Scholar Antiretroviral therapy has fundamentally changed the natural history of HIV infection in terms of morbidity, mortality, and rate of transmission. Nevertheless, all treatment cascades show that late diagnosis remains a major obstacle.6Drew RS Rice B Rüütel K et al.HIV continuum of care in Europe and Central Asia.HIV Med. 2017; 18: 490-499Crossref PubMed Scopus (30) Google Scholar Indeed, people with HIV who present late (ie, with a CD4 count below 350 cells per μL, or even less than 200 cells per μL) represent more than 40% of the new diagnoses in Europe annually with no improvement in the past 2 decades.7European Centre for Disease Prevention and ControlHIV/AIDS surveillance in Europe 2018 (2017 data).https://www.ecdc.europa.eu/en/publications-data/hivaids-surveillance-europe-2018-2017-dataDate: Nov 28, 2018Date accessed: September 1, 2022Google Scholar Late diagnosis, with a mortality rate of around 5%, not only represents a clinical challenge for the individual but is also the main obstacle for HIV elimination.8Martin-Iguacel R Reyes-Urueña J Bruguera A et al.Determinants of long-term survival in late HIV presenters: the prospective PISCIS cohort study.EClinicalMedicine. 2022; 52101600Summary Full Text Full Text PDF PubMed Scopus (1) Google Scholar Important reasons driving late presentation include poor understanding of personal risk, and social, interpersonal, and internalised stigma. The intense media attention surrounding the monkeypox emergency, and the access to large vaccination events for people who might be at risk of acquiring HIV infection or might be unaware of their HIV status, represents a golden opportunity. Each vaccination event offers a unique opportunity, either to increase HIV and other sexually transmitted disease testing, or to prevent new infections. Indeed, the approach of public health agencies to the vaccination effort should not merely replicate the vaccination events for SARS-CoV-2 but should offer an integrated sexual health clinic. This person-centred, holistic approach to sexual health could entail HIV testing and promotion of rapid antiretroviral therapy for people with HIV or evaluation for PrEP in case of a negative HIV test. This could also be an opportunity to spark further activism around PrEP in countries such as Italy where PrEP is still not reimbursed. Unfortunately, this person-centred approach to sexual health has not been adopted as standard of care. Thornhill and colleagues4Thornhill JP Barkati S Walmsley S et al.Monkeypox virus infection in humans across 16 countries—April–June, 2022.N Engl J Med. 2022; 387: 679-691Crossref PubMed Scopus (225) Google Scholar described that among the 310 cases of unknown or negative previous HIV tests, only 122 (39%) patients underwent a HIV test after monkeypox diagnosis, and two (2%) of those had positive results. The WHO declaration of public health emergency for monkeypox reflects the growing number of infections, which fortunately have not been associated with severe outcomes or death.4Thornhill JP Barkati S Walmsley S et al.Monkeypox virus infection in humans across 16 countries—April–June, 2022.N Engl J Med. 2022; 387: 679-691Crossref PubMed Scopus (225) Google Scholar Amid the media attention around COVID-19 and now monkeypox, it should not be forgotten that the HIV pandemic is ongoing, with more than 50 million people living with HIV globally and thousands of deaths, not only in low-income and middle-income countries, but also in high-income countries, especially among late presenters. In the attempt to decrease late presentation, many approaches have been tried; for example, the HIV in Europe initiative has provided a list of indicator diseases to identify people who should be tested for HIV, including sexually transmitted diseases, lymphomas, and thrombocytopenia.9HIV in Europe SecretariatHIV indicator conditions: guidance for implementing HIV testing in adults in health care settings. HIV in Europe, Copenhagen2011Google Scholar Other approaches have included testing people in emergency departments.10Orkin C Flanagan S Wallis E et al.Incorporating HIV/hepatitis B virus/hepatitis C virus combined testing into routine blood tests in nine UK Emergency Departments: the “Going Viral” campaign.HIV Med. 2016; 17: 222-230Crossref PubMed Scopus (44) Google Scholar In our opinion, not only should monkeypox itself be included in this list of indicator diseases for HIV testing, but also, everyone undergoing vaccination should be tested for HIV and, if they are negative, counselled about PrEP. CM reports grants and travel support from Gilead, personal fees from ViiV Healthcare, and participation on advisory boards from CORIMUNO, ViiV Healthcare, ROCHE, Janssen, Gilead Sciences, and Merck Sharp & Dohme. GG reports grants, personal fees, travel support, and participation on advisory boards from Gilead Sciences, ViiV Healthcare, and Merck Sharp & Dohme, and personal fees from Janssen. CO reports grants, personal fees, and travel sponsorship from ViiV Healthcare, and grants and personal fees from GlaxoSmithKline, Gilead Sciences, Merck Sharp & Dohme, Janssen, and AstraZeneca." @default.
• W4303473147 created "2022-10-08" @default.
• W4303473147 creator A5013078758 @default.
• W4303473147 creator A5039738554 @default.
• W4303473147 creator A5082570595 @default.
• W4303473147 date "2022-11-01" @default.
• W4303473147 modified "2023-09-25" @default.
• W4303473147 title "Monkeypox vaccination—an opportunity for HIV prevention" @default.
• W4303473147 cites W2286361385 @default.
• W4303473147 cites W2580201580 @default.
• W4303473147 cites W4286383196 @default.
• W4303473147 cites W4289636240 @default.
• W4303473147 cites W4298676460 @default.
• W4303473147 cites W58724200 @default.
• W4303473147 doi "https://doi.org/10.1016/s2352-3018(22)00292-2" @default.
• W4303473147 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36215986" @default.
• W4303473147 hasPublicationYear "2022" @default.
• W4303473147 type Work @default.
• W4303473147 citedByCount "6" @default.
• W4303473147 countsByYear W43034731472022 @default.
• W4303473147 countsByYear W43034731472023 @default.
• W4303473147 crossrefType "journal-article" @default.
• W4303473147 hasAuthorship W4303473147A5013078758 @default.
• W4303473147 hasAuthorship W4303473147A5039738554 @default.
• W4303473147 hasAuthorship W4303473147A5082570595 @default.
• W4303473147 hasBestOaLocation W43034731471 @default.
• W4303473147 hasConcept C104317684 @default.
• W4303473147 hasConcept C159047783 @default.
• W4303473147 hasConcept C17744445 @default.
• W4303473147 hasConcept C185592680 @default.
• W4303473147 hasConcept C199539241 @default.
• W4303473147 hasConcept C22070199 @default.
• W4303473147 hasConcept C2778011067 @default.
• W4303473147 hasConcept C2778190748 @default.
• W4303473147 hasConcept C2779473830 @default.
• W4303473147 hasConcept C2781356689 @default.
• W4303473147 hasConcept C2909828532 @default.
• W4303473147 hasConcept C3013748606 @default.
• W4303473147 hasConcept C40767141 @default.
• W4303473147 hasConcept C512399662 @default.
• W4303473147 hasConcept C55493867 @default.
• W4303473147 hasConcept C71924100 @default.
• W4303473147 hasConceptScore W4303473147C104317684 @default.
• W4303473147 hasConceptScore W4303473147C159047783 @default.
• W4303473147 hasConceptScore W4303473147C17744445 @default.
• W4303473147 hasConceptScore W4303473147C185592680 @default.
• W4303473147 hasConceptScore W4303473147C199539241 @default.
• W4303473147 hasConceptScore W4303473147C22070199 @default.
• W4303473147 hasConceptScore W4303473147C2778011067 @default.
• W4303473147 hasConceptScore W4303473147C2778190748 @default.
• W4303473147 hasConceptScore W4303473147C2779473830 @default.
• W4303473147 hasConceptScore W4303473147C2781356689 @default.
• W4303473147 hasConceptScore W4303473147C2909828532 @default.
• W4303473147 hasConceptScore W4303473147C3013748606 @default.
• W4303473147 hasConceptScore W4303473147C40767141 @default.
• W4303473147 hasConceptScore W4303473147C512399662 @default.
• W4303473147 hasConceptScore W4303473147C55493867 @default.
• W4303473147 hasConceptScore W4303473147C71924100 @default.
• W4303473147 hasFunder F4320311022 @default.
• W4303473147 hasIssue "11" @default.
• W4303473147 hasLocation W43034731471 @default.
• W4303473147 hasLocation W43034731472 @default.
• W4303473147 hasLocation W43034731473 @default.
• W4303473147 hasOpenAccess W4303473147 @default.
• W4303473147 hasPrimaryLocation W43034731471 @default.
• W4303473147 hasRelatedWork W1719237633 @default.
• W4303473147 hasRelatedWork W2085274006 @default.
• W4303473147 hasRelatedWork W2111548447 @default.
• W4303473147 hasRelatedWork W2142207009 @default.
• W4303473147 hasRelatedWork W4252039360 @default.
• W4303473147 hasRelatedWork W4281843992 @default.
• W4303473147 hasRelatedWork W4292495373 @default.
• W4303473147 hasRelatedWork W4292583017 @default.
• W4303473147 hasRelatedWork W4293659970 @default.
• W4303473147 hasRelatedWork W4297263274 @default.
• W4303473147 hasVolume "9" @default.
• W4303473147 isParatext "false" @default.
• W4303473147 isRetracted "false" @default.
• W4303473147 workType "article" @default.